Efficacy of Oral vs. Intravenous Acetaminophen

Overview

The comparative efficacy of intravenous (IV) to oral (PO-'per os') acetaminophen in the management of postoperative pain is understudied and largely unknown. In this observer blinded randomized clinical trial, investigators aim to determine the comparative efficacy of PO (preoperative) vs. IV (intraoperative) acetaminophen in a sinus surgery population.

Full Title of Study: “The Comparative Efficacy of Oral vs. Intravenous Acetaminophen in Sinus Surgery Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: September 2, 2016

Detailed Description

The comparative efficacy of intravenous (IV) to oral (PO-'per os') acetaminophen is understudied and largely unknown. Intravenous acetaminophen has been available since 2010 (http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022450lbl.pdf) and has proven superiority over placebo in human clinical trials. It is clearly advantageous in patients who cannot take oral medications. Similarly, oral acetaminophen has proven efficacy in the management of postoperative pain. However, in patients who can receive either formulation the incremental cost of the IV formulation, both to the Health System and patient, is substantial. This incremental cost would be justifiable if there were clear efficacy or safety data to support the preferential use of IV over PO acetaminophen. However, there is no evidence of superior safety and there are only two studies to our knowledge investigating the question of comparative efficacy. Fenlon et al. randomized 130 patients undergoing 3rd molar (i.e., wisdom tooth) removal to IV vs. PO acetaminophen and found that PO acetaminophen was non-inferior to IV acetaminophen. The primary endpoint was postoperative pain score 1h after surgery. No safety concerns were identified in either group. Pettersson et al. randomized cardiac surgery patients to IV or PO acetaminophen, starting immediately postoperatively through the following morning, and found a significant opioid sparing effect of IV acetaminophen but no difference in pain scores or nausea. IV acetaminophen avoids first-pass hepatic metabolism and therefore generates higher serum and cerebrospinal fluid (CSF)/brain levels than does PO acetaminophen (http://ofirmev.com/Pharmacokinetics/). Based on the pharmacokinetic data, one can hypothesize that IV acetaminophen would be superior to PO acetaminophen at time points where serum and/or cerebrospinal fluid drug levels are higher.

Interventions

  • Drug: Oral Acetaminophen
    • 1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
  • Drug: Intravenous acetaminophen
    • 400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.

Arms, Groups and Cohorts

  • Active Comparator: Oral Acetaminophen
    • Oral Acetaminophen 1-hour before surgery
  • Active Comparator: Intravenous Acetaminophen
    • Intravenous Acetaminophen within 1-hour prior to anesthetic emergence

Clinical Trial Outcome Measures

Primary Measures

  • Postoperative Pain Score on the Scale of 10 (0=No Pain and 10=Worst Pain)
    • Time Frame: 1-h postoperatively
    • Pain score on the scale of 10 at 1-h postoperatively in the Post-Anesthesia Care Unit (PACU)

Secondary Measures

  • Morphine Equivalents of Postoperative Opioid Usage
    • Time Frame: an expected average of 6 hours
    • Total amount of postoperative opioid usage at Postoperative Anesthesia Care Unit (PACU), an expected average of 6 hours

Participating in This Clinical Trial

Inclusion Criteria

  • Adult patients aged 18 years or older – Undergoing elective sinus surgery at Zale Lipshy Hospital Exclusion Criteria:

  • Inability of the patient to follow directions or comprehend either English or Spanish language. – Disorders of the liver which would make acetaminophen contraindicated (such as hepatitis, liver failure, prior liver transplant, etc). – Patients with chronic pain manifest by a baseline pain score > 4/10 – Chronic opioid use (>2 weeks continuously), or illicit drug abuse – Body weight < 50 kg. – Patients with contraindications to any of the study drugs (such as Malignant Hyperthermia susceptible, celecoxib or sulfa allergy, etc.). – Patients who have taken analgesic medications on the morning of surgery (prior to arrival). – Allergy to acetaminophen

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Texas Southwestern Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David McDonagh, MD, Principal Investigator, UT Southwestern Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.